ICAM-1, GRP-78, and NFkB gene polymorphisms and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)

Abstract

4134 Background: We evaluated polymorphisms of genes involved in angiogenesis, cell proliferation, and cell-cell or cell-matrix adhesion as potential predictors of clinical outcome in pts with mCRC...